Tolerance of COVID-19 vaccination in patients with systemic lupus erythematosus: the international VACOLUP study
- PMID: 34312612
- PMCID: PMC8294805
- DOI: 10.1016/S2665-9913(21)00221-6
Tolerance of COVID-19 vaccination in patients with systemic lupus erythematosus: the international VACOLUP study
Conflict of interest statement
RF has received consultancy fees from Pfizer and Janssen (unrelated to the VACOLUP study). MP has received consultancy fees from GSK and Pfizer (unrelated to the VACOLUP study). MFU-G reports grants from Janssen and Pfizer, and support for attending meetings and/or travel from Pfizer and Abbvie (unrelated to the VACOLUP study). LA has received consultancy fees from Pfizer and AstraZeneca (unrelated to the VACOLUP study). All other authors declare no competing interests. RF and LA verified all the data in the study. We wish to acknowledge the crucial role of the following patient associations: LupusEurope (@LupusEurope), Agrupación Lupus Chile (@Lupus_Chile), Lupus UK, Lupus France, AFL+, and Gruppo LES Italiano, in the dissemination of the survey. RF, LK, MD, and LA conceived the study. RF and LA curated the data. All authors did the investigation. RF, LK, MD, and LA devised the methodology. RF and LA wrote the original draft of the manuscript. All authors reviewed and edited the manuscript.
References
-
- McGill COVID-19 Vaccine Tracker Team COVID19 Vaccine Tracker. https://covid19.trackvaccines.org/vaccines/
-
- Geisen UM, Berner DK, Tran F, et al. Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort. Ann Rheum Dis. 2021 doi: 10.1136/annrheumdis-2021-220272. published online March 24. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
